Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sgp(schering plough) -- Ignore unavailable to you. Want to Upgrade?

To: Home-Run who wrote (110)	11/29/2003 9:59:19 AM
From: Home-Run	Read Replies (1) \| Respond to of 117

7:43AM Merck investors clamor for new strategy -- Schering-Plough deal seen as a possibility (MRK) 41.02: The Wall Street Journal reports that, after four of co's eleven research bets have come up short, some investors are clamoring for a new strategy -- one focused on mergers. One possibility often mentioned is a merger with Schering-Plough (SGP). Merck and Schering-Plough already cooperate in selling an anticholesterol pill, and Schering-Plough's chief executive is seen as a candidate for the top post in the event of a merger. However, Merck's CEO continues to be opposed to mergers. Schering-Plough's CEO said in an interview on Nov. 18 that he is open to the idea of a merger with Merck or another large company but only after Schering-Plough's fortunes have fully recovered from the loss of its patent protection on allergy drug Claritin, which he doesn't expect to happen until at least 2005.